Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer.
Piulats JM, Kondo J, Endo H, Ono H, Hagihara T, Okuyama H, Nishizawa Y, Tomita Y, Ohue M, Okita K, Oyama H, Bono H, Masuko T, Inoue M. Piulats JM, et al. Among authors: masuko t. Oncotarget. 2018 Mar 23;9(22):15968-15983. doi: 10.18632/oncotarget.24641. eCollection 2018 Mar 23. Oncotarget. 2018. PMID: 29662620 Free PMC article.
Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role.
Yuan Q, Furukawa T, Tashiro T, Okita K, Jin ZH, Aung W, Sugyo A, Nagatsu K, Endo H, Tsuji AB, Zhang MR, Masuko T, Inoue M, Fujibayashi Y, Saga T. Yuan Q, et al. Among authors: masuko t. PLoS One. 2015 Nov 16;10(11):e0143076. doi: 10.1371/journal.pone.0143076. eCollection 2015. PLoS One. 2015. PMID: 26571416 Free PMC article.
Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers.
Okita K, Okazaki S, Uejima S, Yamada E, Kaminaka H, Kondo M, Ueda S, Tokiwa R, Iwata N, Yamasaki A, Hayashi N, Ogura D, Hirotani K, Yoshioka T, Inoue M, Masuko K, Masuko T. Okita K, et al. Among authors: masuko t, masuko k. Oncotarget. 2020 Jan 7;11(1):31-45. doi: 10.18632/oncotarget.27414. eCollection 2020 Jan 7. Oncotarget. 2020. PMID: 32002122 Free PMC article.
Dual-targeting therapy against HER3/MET in human colorectal cancers.
Yamasaki A, Miyake R, Hara Y, Okuno H, Imaida T, Okita K, Okazaki S, Akiyama Y, Hirotani K, Endo Y, Masuko K, Masuko T, Tomioka Y. Yamasaki A, et al. Among authors: masuko t. Cancer Med. 2023 Apr;12(8):9684-9696. doi: 10.1002/cam4.5673. Epub 2023 Feb 7. Cancer Med. 2023. PMID: 36751113 Free PMC article.
Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene.
Okita K, Hara Y, Okura H, Hayashi H, Sasaki Y, Masuko S, Kitadai E, Masuko K, Yoshimoto S, Hayashi N, Sugiura R, Endo Y, Okazaki S, Arai S, Yoshioka T, Matsumoto T, Makino Y, Komiyama H, Sakamoto K, Masuko T. Okita K, et al. Among authors: masuko s, masuko t, masuko k. Cancer Sci. 2021 Feb;112(2):563-574. doi: 10.1111/cas.14741. Epub 2020 Dec 11. Cancer Sci. 2021. PMID: 33211385 Free PMC article.
Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy.
Ohkawa M, Ohno Y, Masuko K, Takeuchi A, Suda K, Kubo A, Kawahara R, Okazaki S, Tanaka T, Saya H, Seki M, Enomoto T, Yagi H, Hashimoto Y, Masuko T. Ohkawa M, et al. Among authors: masuko t, masuko k. Biochem Biophys Res Commun. 2011 Mar 25;406(4):649-55. doi: 10.1016/j.bbrc.2011.02.135. Epub 2011 Mar 1. Biochem Biophys Res Commun. 2011. PMID: 21371427
251 results